FMP

FMP

Enter

DMAC - DiaMedica Therapeuti...

Profile of DiaMedica Therapeutics Inc.(DMAC), DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neu

photo-url-https://financialmodelingprep.com/image-stock/DMAC.png

DiaMedica Therapeutics Inc.

DMAC

NASDAQ

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

2.39 USD

-0.1 (-4.18%)

About

ceo

Mr. Dietrich John Pauls MBA

sector

Healthcare

industry

Biotechnology

website

https://www.diamedica.com

exchange

NASDAQ

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CIK

0001401040

ISIN

CA25253X2077

CUSIP

25253X207

Address

Two Carlson Parkway

Phone

763 612 6755

Country

US

Employee

18

IPO Date

Aug 3, 2012

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep